Professional
Added to YB: 2025-09-22
Pitch date: 2025-09-18
DXCM [bearish]
DexCom, Inc.
+10.72%
current return
Author Info
Hunterbrook Media publishes investigative and global reporting with no ads or paywalls. Their mission is to bring visibility to under-covered regions and accountability to under-scrutinized sectors. Sign up for the newsletter.
Company Info
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
Market Cap
$23.5B
Pitch Price
$75.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
21.49
P/E
33.52
EV/Sales
5.04
Sector
Health Care Equipment and Supplies
Category
N/A
Dexcom’s Fatal Flaws
DXCM short: G7 CGM devices linked to hospitalizations & deaths due to inaccurate readings; FDA found unauthorized design change to membrane coating that performed worse by 'every accuracy metric'; generated 22% more accuracy complaints vs market share; DSO at 106 days suggesting revenue manipulation; executive exodus incl CEO; Abbott taking share with superior device; accounting issues mirror 2024's 40% stock drop.
Read full article (25 min)